winhorse Xpeng ( XPEV ) shares have fallen more than 5% to $14.10 on Thursday, extending their weekly decline to nearly 10%. The stock sharply lagged the broader S&P 500 ( SP500 )'s YTD gain of 6.22% with a 30.97% decline over the same period. The recent weakness worsened after Xpeng delivered Q1 results on May 28. The company reported a non-GAAP EPS loss of $0.26, missing estimates by $0.10, whil...
winhorse Xpeng ( XPEV ) shares have fallen more than 5% to $14.10 on Thursday, extending their weekly decline to nearly 10%. The stock sharply lagged the broader S&P 500 ( SP500 )'s YTD gain of 6.22% with a 30.97% decline over the same period. The recent weakness worsened after Xpeng delivered Q1 results on May 28. The company reported a non-GAAP EPS loss of $0.26, missing estimates by $0.10, while revenue of $1.89B fell 17.6% YoY. Vehicle deliveries dropped 33.3% to 62.7K units, the net loss widened 168.7% to RMB 1.78B, and the vehicle margin slipped to 12.1% from 13.0% in Q4 due to higher memory chip and battery costs. Even R&D spending also jumped 46.8% to RMB 2.91B, adding pressure on profitability. Seeking Alpha analyst Julia Ostian noted that "weaker sales, rising losses, and geopolitical risks make the stock less attractive in the near term." However, management is betting on a growth. Chairman and CEO He Xiaopeng expects a rebound with four new vehicle launches this year and guided Q2 revenue to RMB 19.60B-RMB 20.80B, implying sequential growth of 50.4%-59.6%, with deliveries expected to rise to 100K-106K vehicles. The company is also expanding beyond EVs. At the CVPR 2026 conference in Denver, XPeng showcased its physical AI technologies alongside Tesla ( TSLA ), NVIDIA ( NVDA ), and Waymo ( WAYMO ). Beyond autonomous vehicles, XPeng is pushing deeper into robotics . Reportedly, He Xiaopeng will personally lead the robotics unit as the company approaches the "eve of mass production and commercialization" of its IRON humanoid robots. The robots are expected to first appear in the company's stores before commercial deliveries begin in China and overseas in 2027. For now, negative momentum continues to dominate the stock. XPeng stock carries a Quant Rating of 2.60, implying a Hold view, even as Seeking Alpha analysts and Wall Street analysts maintain Buy ratings above 4. However, strong delivery guidance and growing AI ambitions suggest the stock's recent cras...
Shares of Marvell Technology (NASDAQ:MRVL) are up 8% today, trading at around $273 in midday action on Thursday, June 11. The move extends a remarkable run that has the stock up 57% over the past month heading into its scheduled index debut. The catalyst is well known. S&P Dow Jones Indices confirmed in its June ... Marvell Just Ripped 57% in a Month. Will the June 22 S&P 500 Listing Be a Sell-the...
Shares of Marvell Technology (NASDAQ:MRVL) are up 8% today, trading at around $273 in midday action on Thursday, June 11. The move extends a remarkable run that has the stock up 57% over the past month heading into its scheduled index debut. The catalyst is well known. S&P Dow Jones Indices confirmed in its June ... Marvell Just Ripped 57% in a Month. Will the June 22 S&P 500 Listing Be a Sell-the-News Event?
Iryna Tolmachova/iStock Editorial via Getty Images Bank of Canada policymakers are finding themselves caught between rising inflation risks and a softening economy, with patience now the clearest policy path. Andrew Kelvin, Head of Canada and Global Rates Strategy at TD Securities, says the central bank is taking a “do no harm” approach, waiting for clearer signals before deciding whether the next...
Iryna Tolmachova/iStock Editorial via Getty Images Bank of Canada policymakers are finding themselves caught between rising inflation risks and a softening economy, with patience now the clearest policy path. Andrew Kelvin, Head of Canada and Global Rates Strategy at TD Securities, says the central bank is taking a “do no harm” approach, waiting for clearer signals before deciding whether the next move is a hike or a cut. Transcript Greg Bonnell: The Bank of Canada has held its key interest rate in its latest decision. But with fears about inflation and also slowing economic growth, how much longer can our central bank stay on hold? Joining us now to discuss is Andrew Kelvin, Head of Canadian and Global Rate Strategy with TD Securities. Andrew, always great to have you here on Bank of Canada today. Andrew Kelvin: Always a pleasure to be here. Thank you for having me. Greg Bonnell: All right. So is this another one of those things where the bank's in a bit of a hard place, doesn't know what's going to happen in the future, doesn't even know if it's going to be a hike, or a cut, or a hold, and for how long? Andrew Kelvin: So I'm going to use a really tortured analogy here that just came to me. So I don't know if it will work. Greg Bonnell: All right. Fresh one. Andrew Kelvin: When you're in quicksand, you're not supposed to struggle. They are in a very hard place. Governor Macklem referred to his dilemma being sort of caught between increasing inflation pressures and weak growth. The best thing for the Bank of Canada to do here is to not struggle. It's to be patient and let the economy sort of work its way out of it -- take the shocks as they come, rather than trying to anticipate what's happening, because the geopolitical uncertainty, it is just so high. Governor Macklem talked about if we were to see additional trade restrictions put on Canada by the United States, for example, perhaps they might need to cut. If energy prices remain high for a long time and pressure...
Midfielder missed final training session before Haiti game ‘Hopefully that doesn’t spread,’ said Kenny McLean Scotland are confident Scott McTominay will be fit to face Haiti on Saturday despite the midfielder sitting out training on Thursday due to a stomach complaint. McTominay, widely considered Scotland’s most influential player, was a notable absentee as Steve Clarke put his players through t...
Midfielder missed final training session before Haiti game ‘Hopefully that doesn’t spread,’ said Kenny McLean Scotland are confident Scott McTominay will be fit to face Haiti on Saturday despite the midfielder sitting out training on Thursday due to a stomach complaint. McTominay, widely considered Scotland’s most influential player, was a notable absentee as Steve Clarke put his players through their paces for a final time in North Carolina before departing for Boston. There, Scotland will play their first World Cup match in 28 years. Continue reading...
British driver says pressure is off following bad run Antonelli 68 points ahead of Mercedes teammate George Russell insists the pressure is off in the battle for the Formula One drivers’ championship after a succession of mishaps this season – combined with the exemplary form of his Mercedes teammate , Kimi Antonelli – left him 68 points off the pace. Sunday’s round seven is the newly styled Barce...
British driver says pressure is off following bad run Antonelli 68 points ahead of Mercedes teammate George Russell insists the pressure is off in the battle for the Formula One drivers’ championship after a succession of mishaps this season – combined with the exemplary form of his Mercedes teammate , Kimi Antonelli – left him 68 points off the pace. Sunday’s round seven is the newly styled Barcelona-Catalunya Grand Prix, with the Spanish Grand Prix shifting to a new venue in Madrid in September. Mercedes are expected to excel again this weekend, but it is the 19-year-old Antonelli who has established a firm grip on the drivers’ championship after five consecutive victories . Continue reading...
Automobiles are increasingly using sophisticated technology suppliers to make their vehicles more energy efficient and safer. Investors are currently weighing the merits of Cognex Corp. (NASDAQ:CGNX) and Power Integrations (NASDAQ:POWI) . Cognex specializes in the sophisticated software and hardware that allow machines to see, while Power Integrations focuses on the chips that manage power convers...
Automobiles are increasingly using sophisticated technology suppliers to make their vehicles more energy efficient and safer. Investors are currently weighing the merits of Cognex Corp. (NASDAQ:CGNX) and Power Integrations (NASDAQ:POWI) . Cognex specializes in the sophisticated software and hardware that allow machines to see, while Power Integrations focuses on the chips that manage power conversion. Both serve critical roles in modern industry, but their financial profiles and market risks offer distinct paths for your capital. Cognex is a global leader in machine vision technology, providing sensors and software that automate manufacturing tasks. The company occupies a prominent position among tech stocks due to its specialized focus on machine vision. Its systems are used to inspect, identify, and guide products in the logistics, automotive, and electronics industries. Continue reading
An expanded deal between Novartis ( NVS ) and privately held Orionis Biosciences for molecular glue drugs on Thursday boosted shares of Monte Rosa Therapeutics ( GLUE ), Kymera Therapeutics ( KYMR ), and Nurix Therapeutics ( NRIX ), which focus on similar drugs. As part of the multiyear partnership, the Swiss drugmaker will leverage Orionis’ Allo-Glue platform and its AI-based drug discovery capab...
An expanded deal between Novartis ( NVS ) and privately held Orionis Biosciences for molecular glue drugs on Thursday boosted shares of Monte Rosa Therapeutics ( GLUE ), Kymera Therapeutics ( KYMR ), and Nurix Therapeutics ( NRIX ), which focus on similar drugs. As part of the multiyear partnership, the Swiss drugmaker will leverage Orionis’ Allo-Glue platform and its AI-based drug discovery capabilities to discover and advance molecular glue medicines for various diseases. In exchange, Waltham, Massachusetts-based Orionis will receive $40M upfront from Novartis ( NVS ) in addition to milestone payments worth up to $1.4B and tiered royalties on net sales of potential products developed under the collaboration. “We are excited to deepen our collaboration with Orionis and to explore the full potential of molecular glue modalities across multiple therapeutic areas,” said Novartis’ ( NVS ) head of Discovery Sciences, John Tallarico. The deal comes at a time when Big Pharma is increasingly turning attention to the molecular glue technology, which enables targeted degradation of disease-causing proteins. In June 2025, Gilead ( GILD ) inked an exclusive deal worth up to $750M with Kymera ( KYMR ) to license a CDK2-directed MGD program targeting cancer. More on Novartis, Kymera Therapeutics, etc. Nurix Therapeutics Deal With Roche Is Worth Betting On Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases - Slideshow Biggest stock movers Monday: NRIX, INTC, and more Nurix surges 43% on up to $3B cancer drug deal with Roche
A safety inquiry into the WellBN clinic in Brighton found 78 children were potentially harmed after being given gender medication without proper checks.
A safety inquiry into the WellBN clinic in Brighton found 78 children were potentially harmed after being given gender medication without proper checks.
NASA pushed its Deep Space Network beyond its limits during the Artemis I mission nearly four years ago. The global array of deep space communications antennas couldn't keep up with the routine demands of 40 robotic science missions and the extraordinary surge required by NASA's Orion space capsule as it flew around the Moon. The experience in late 2022 reduced or delayed downlinks from several hi...
NASA pushed its Deep Space Network beyond its limits during the Artemis I mission nearly four years ago. The global array of deep space communications antennas couldn't keep up with the routine demands of 40 robotic science missions and the extraordinary surge required by NASA's Orion space capsule as it flew around the Moon. The experience in late 2022 reduced or delayed downlinks from several high-profile science missions, including the James Webb Space Telescope and Mars rovers, as the data-hungry Artemis I mission took priority on NASA's communications network. And that was before the first Artemis mission with astronauts onboard. When Artemis II launched April 1, NASA called upon the Deep Space Network (DSN) again to connect Mission Control to the Orion capsule as it soared more than a quarter of a million miles from Earth. With a crew of four flying inside the spacecraft, the agency's appetite for data from Orion on Artemis II was even higher than it was on Artemis I. But at a little more than nine days, the Artemis II mission was shorter than the 25 days Artemis I spent in space, helping alleviate the communications overload. Artemis I also launched 10 small CubeSats into deep space, many of which required tracking and telecom services from the DSN. Artemis II carried fewer CubeSats. Read full article Comments